GeneGo said today that it has been awarded a Phase II Small Business Innovation Research grant from the National Cancer Institute to continue the development of its MetaMiner (Oncology) platform.
The award is worth $625,485 according to an NIH database. It follows a $200,000 Phase I SBIR that the company was awarded in 2008 to adopt its MetaMiner pathway analysis platform for cancer research (BioInform 6/20/2008).
Investigators from Harvard Medical School, Johns Hopkins University, the Translational Genomics Institute, the Van Andel Institute, and several undisclosed pharmaceutical companies are working with GeneGo researchers to develop the platform.
According to the company, the platform will be used for target discovery, translational cancer research, and personalized diagnostics.
According to the grant abstract, the company used the Phase I funding to develop "several novel algorithms for quantitative functional analysis of large multi-patient datasets and offered new methods for cross-analysis of cancer datasets of different type." The company also designed "a framework for manual annotation of cancer pathways, assays and gene-disease causative associations."
In Phase II, GeneGo plans to "implement the algorithms into a robust 'rich client' analytical platform and complete annotation of cancer data," the grant abstract states.